Markets

Drugmakers Race to Challenge Novo Nordisk and Eli Lilly's Obesity Drug Dominance

Pharmaceutical companies bet on new approaches to crack into the lucrative weight loss market currently controlled by two industry giants.

Drugmakers Race to Challenge Novo Nordisk and Eli Lilly's Obesity Drug Dominance
Read the full reporting at CNBC Markets.

Originally reported by CNBC Markets.

obesity drugs pharmaceutical companies Novo Nordisk Eli Lilly GLP-1 weight loss